Centessa axes lead program after a patient in kidney disease safety study is hospitalized
Less than four months after dosing the first patients in a pivotal study for its lead program, Centessa is instead reversing course in a big way.
The biotech said Thursday that it would discontinue development for its lead program, the kidney drug lixivaptan, after dosing the first Phase III patient on Feb. 24. Centessa said it made the decision once a patient in a safety study was hospitalized for elevated liver enzyme levels, and it realized the drug wouldn’t be able to deliver a differentiated profile from an already approved drug in autosomal dominant polycystic kidney disease, which had been the primary indication.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.